Mayo Clinic, Hibiscus BioVentures, Innoforce partner on cell and gene therapy accelerator

By The Science Advisory Board staff writers

August 31, 2022 -- The Mayo Clinic, Hibiscus BioVentures, and Innoforce have teamed up to advance new cures for serious and complex diseases with cell and gene therapies that address unmet patient needs.

Mayflower BioVentures, a cell and gene therapy accelerator, is being launched under the academic-industry partnership which is meant to identify and form independent companies to further development of Mayo Clinic technologies through preclinical and early feasibility studies.

According to the August 31 announcement, the Mayo Clinic has generated a portfolio of next-generation immune system modulators and multiple novel therapeutics in cell and gene therapy. The accelerator is envisioned as a springboard for startups to leverage Mayo's research capabilities and transition scientific discoveries from the lab bench to patients' bedsides.

"We believe this collaboration can bridge the gap between industry and innovative cell and gene therapy research, enabling emerging startups to navigate the challenges of producing meaningful, novel therapeutics that transform health and medicine," Andrew Danielsen, chair of Mayo Clinic Ventures, said in a statement.

Mayo Clinic, National Resilience to create center for biomanufacturing regenerative technologies
The Mayo Clinic and biotech company National Resilience have announced a strategic collaboration in biomanufacturing to deliver novel biotherapeutics...
Mustang Bio, Mayo Clinic partner on viral CAR T technology
Mustang Bio announced it is collaborating with the Mayo Clinic on a novel technology for CAR T-cell therapies.

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter